The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists.
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Crohn's Arthritis Linked to E. Coli Infection
Articular manifestations of Crohn's disease affects a significant number of patients with either oligoarticular or RA-like polyarthritis or spondyloarthritis.
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology.
FDA Issues Draft Guidance on Biosimilar Interchangeability
Last week the Food and Drug Administration released its draft guidance on the interchangeability between biosimilars and originator biologic drugs. (Citation source: http://buff.ly/2k9f79y)
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Social
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
Janet Pope @Janetbirdope ( View Tweet )
5 years 6 months ago
#EULAR2020 OP0167 Results are finally in!!
MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
k dao @KDAO2011 ( View Tweet )
5 years 6 months ago
Review of Rheumatic Sxs with Immune checkpoint inhibitors - Common are inflammatory arthritis, PMR & myositis. Non-MSK Sxs include sicca, vasculitides and sarcoidosis. SLE and scleroderma are extremely rare. Majority can be Rx w/ steroids. https://t.co/hku5L7hypo
Dr. John Cush @RheumNow ( View Tweet )
5 years 6 months ago
A patient service Video - How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/hWW0h8wCZn or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5 https://t.co/SldbyCBDeI
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years 6 months ago
Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3
Dr. John Cush @RheumNow ( View Tweet )
5 years 7 months ago
NYC, NYU COVID infected Rheum pts (n 86 RA, PsA, AS, PsO, IBD);
16% Hospitalized. Hosp pts were more likely to be older, w/ HTN, DM, COPD, on Pred, HCQ, MTX, but less likely to be on JAKi, biologic, TNFi (vs ambulatory) https://t.co/UCVndBDc7r https://t.co/ZEk1PFEkXA
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years 7 months ago
ACR has published COVID-19 Recs -American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic by Mikuls Johnson Fraenkel Arasaratnam Baden Bermas Chatham https://t.co/wwpslcLXx2
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years 7 months ago
ACR Guidance for Rheumatic Disease during COVID-19 pandemic #Rheumatology @RheumNow https://t.co/vHav6g4p6Q
Maeve Gamble @MaeveGamble ( View Tweet )
5 years 7 months ago
NICE guidelines on managing rheumatologic conditions during COVID-19 #Rheumatology @RheumNow https://t.co/dQcavsno5N
Maeve Gamble @MaeveGamble ( View Tweet )
5 years 7 months ago
RheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 years 1 month ago
